RMMS Defeats Motion for Preliminary Injunction Involving Generic Tiagabine Hydrochloride Products

December 20, 2012 | Small Molecules

12/20/2012 On December 20, 2012, RMMS successfully defeated Plaintiff Cephalon, Inc.’s motion for preliminary injunction against the firm’s clients, Sun Pharmaceutical Industries, Ltd. and Caraco Pharmaceutical Laboratories, Ltd. (‘Sun’). After briefing and hearing argument and witness testimony on Plaintiff’s motion to enjoin Sun from marketing its generic version of Gabitril®, the U.S. District Court for the District of New Jersey denied Plaintiff’s motion, holding that Plaintiff had failed to demonstrate a likelihood of proving its allegations of patent infringement against Sun. Furthermore, the Court concluded that Sun had raised a substantial question regarding the validity of the patent-in-suit. Deanne Mazzochi, William Rakoczy, Paul Molino, Joseph Jaros, and Anuj Wadhwa are counsel for Sun. This victory continues to place RMMS at the forefront of generic challenges to brand pharmaceutical patents.